- Home
- NTLA vs REX Comparison
NTLA vs REX Comparison
Compare NTLA & REX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTLA
- REX
- Stock Information
- Founded
- NTLA 2014
- REX 1980
- Country
- NTLA United States
- REX United States
- Employees
- NTLA N/A
- REX N/A
- Industry
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- REX Major Chemicals
- Sector
- NTLA Health Care
- REX Industrials
- Exchange
- NTLA Nasdaq
- REX Nasdaq
- Market Cap
- NTLA 1.2B
- REX 1.0B
- IPO Year
- NTLA 2016
- REX N/A
- Fundamental
- Price
- NTLA $25.74
- REX $30.62
- Analyst Decision
- NTLA Buy
- REX Strong Buy
- Analyst Count
- NTLA 19
- REX 1
- Target Price
- NTLA $30.47
- REX $25.00
- AVG Volume (30 Days)
- NTLA 7.7M
- REX 210.5K
- Earning Date
- NTLA 11-06-2025
- REX 08-27-2025
- Dividend Yield
- NTLA N/A
- REX N/A
- EPS Growth
- NTLA N/A
- REX N/A
- EPS
- NTLA N/A
- REX 1.49
- Revenue
- NTLA $52,857,000.00
- REX $650,008,000.00
- Revenue This Year
- NTLA $9.20
- REX $3.27
- Revenue Next Year
- NTLA N/A
- REX $17.11
- P/E Ratio
- NTLA N/A
- REX $20.80
- Revenue Growth
- NTLA 14.99
- REX N/A
- 52 Week Low
- NTLA $5.90
- REX $16.73
- 52 Week High
- NTLA $26.99
- REX $32.83
- Technical
- Relative Strength Index (RSI)
- NTLA 84.32
- REX 24.98
- Support Level
- NTLA $19.89
- REX $30.30
- Resistance Level
- NTLA $21.49
- REX $32.83
- Average True Range (ATR)
- NTLA 1.73
- REX 0.78
- MACD
- NTLA 0.71
- REX 0.62
- Stochastic Oscillator
- NTLA 86.83
- REX 11.46
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
About REX REX American Resources Corporation
REX American Resources Corp operates as a holding company, which engages in investment in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include dried distillers grains, modified distillers grains, and non-food grade corn oil.